South Korea approves AstraZeneca vaccine, advises caution on use for elderly
Foreign
SOUTH Korea’s Central Pharmaceutical Affairs Council has authorized the AstraZeneca/Oxford Coronavirus vaccine but advised caution on its use for elderly people.
The National Institute of Food and Drug Safety Evaluation (NIFDS) said on Friday.
The regulator gathered to decide on the vaccine on Thursday.
“A recommendation was made to approve it, as for the use of the vaccine like in Europe, it is approved for people over 18 years old.
“But precautions say that the decision on the use for those over 65 years should be made with caution, as there is no sufficient data on the use of the vaccine in people over 65,’’ NIFDS director-general Lee Dong-hee told a briefing.
In the future, the country intends to request additional clinical trial data concerning vaccine use for senior people
The vaccine is not recommended for pregnant women.
The regulator also urged caution on vaccine use for lactating women.
South Korea is set to begin the vaccine rollout this month, Prime Minister Chung Sye-Kyun expects AstraZeneca vaccine doses for 2.19 million people to arrive in the first half of 2021.
This year, the country hopes to receive a total of 106 million doses from various manufacturers. (Sputnik/NAN)
– Feb. 5, 2021 @ 11:45GMT |
Related Posts
Koreans, Nigerians celebrate 2024 Nobel Prize laureate, Han Kang
KOREANS and Nigerians in Federal Capital Territory (FCT), on Friday celebrated Korean literary icon, Han Kang, for winning the 2024 Nobel...
Read MoreMorocco accelerates regionalisation process with 4 new agreements
TANGIER (Morocco), Dec. 21, 2024 (NAN) The Kingdom of Morocco’s 12 regions and several ministerial departments, have signed four framework...
Read MoreSouth Korean President Fails To Appear Before Corruption Watchdog
SOUTH Korea’s impeached President Yoon Suk Yeol failed to appear before the country’s corruption watchdog on Wednesday, it said, after...
Read MoreMost Read
Subscribe to Our Newsletter
Keep abreast of news and other developments from our website.